{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:33:22Z","timestamp":1761863602500},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.thromres.2016.04.025","type":"journal-article","created":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T11:45:57Z","timestamp":1462103157000},"page":"202-209","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The effect of activated clotting time values for patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"144","author":[{"given":"Yi-Yue","family":"Gui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang-Yang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bao-Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Bo","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng-Ju","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.thromres.2016.04.025_bb0005","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1056\/NEJMsa053935","article-title":"Explaining the decrease in U.S. deaths from coronary disease, 1980\u20132000","volume":"356","author":"Ford","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.thromres.2016.04.025_bb0010","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1161\/CIR.0b013e3182456d46","article-title":"Heart disease and stroke statistics\u20132012 update: a report from the American Heart Association","volume":"125","author":"Roger","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2016.04.025_bb0015","unstructured":"Centers for Disease Control and Prevention. Summary health statistics tables for US adults: National Health Interview Survey, 2014. [Internet]. Cited 2016 Apr 1. Available from: http:\/\/ftp.cdc.gov\/pub\/Health_Statistics\/NCHS\/NHIS\/SHS\/2014_SHS_Table_A-1.pdf."},{"issue":"15","key":"10.1016\/j.thromres.2016.04.025_bb0020","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1161\/CIRCULATIONAHA.111.047480","article-title":"Twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987\u20132008","volume":"125","author":"Rosamond","year":"2012","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.thromres.2016.04.025_bb0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.thromres.2016.04.025_bb0030","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.ahj.2013.09.004","article-title":"Balancing the risk of mortality and major bleeding in the treatment of NSTEMI patients - a report from the National Cardiovascular Data Registry","volume":"166","author":"Desai","year":"2013","journal-title":"Am. Heart J."},{"issue":"9151","key":"10.1016\/j.thromres.2016.04.025_bb0035","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(98)07332-2","volume":"353","author":"Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators","year":"1999","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.thromres.2016.04.025_bb0040","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.thromres.2016.04.025_bb0045","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0735-1097(94)90590-8","article-title":"Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty","volume":"23","author":"Ferguson","year":"1994","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.thromres.2016.04.025_bb0050","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/01.CIR.103.7.961","article-title":"Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials","volume":"103","author":"Chew","year":"2001","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.thromres.2016.04.025_bb0055","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0735-1097(02)02767-5","article-title":"Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial","volume":"41","author":"Tolleson","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.thromres.2016.04.025_bb0060","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/01.CIR.0000139868.53594.24","article-title":"Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention","volume":"110","author":"Brener","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.thromres.2016.04.025_bb0065","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1002\/ccd.24279","article-title":"Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb\/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction","volume":"81","author":"Rozenman","year":"2013","journal-title":"Catheter. Cardiovasc. Interv."},{"issue":"9","key":"10.1016\/j.thromres.2016.04.025_bb0070","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.amjcard.2009.06.036","article-title":"Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy","volume":"104","author":"Bertrand","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.thromres.2016.04.025_bb0075","unstructured":"GA Wells, B Shea, D O'Connell, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. [Internet]. Cited 2016 Apr 1. Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/nos_manual.pdf."},{"issue":"15","key":"10.1016\/j.thromres.2016.04.025_bb0080","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"J. Am. Med. Assoc."},{"issue":"4","key":"10.1016\/j.thromres.2016.04.025_bb0085","doi-asserted-by":"crossref","first-page":"e002044","DOI":"10.1161\/CIRCINTERVENTIONS.114.002044","article-title":"Activated clotting time and outcomes during percutaneous coronary intervention for non-ST-segment-elevation myocardial infarction: insight from the FUTURA\/OASIS-8 Trial","volume":"8","author":"Ducrocq","year":"2015","journal-title":"Circ. Cardiovasc. Interv."},{"issue":"1","key":"10.1016\/j.thromres.2016.04.025_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","article-title":"Thrombolysis in Myocardial Infarction (TIMI) Trial\u2014phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase","volume":"11","author":"Rao","year":"1988","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.thromres.2016.04.025_bb0095","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 Randomized Trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"J. Am. Med. Assoc."},{"issue":"7414","key":"10.1016\/j.thromres.2016.04.025_bb0100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.thromres.2016.04.025_bb0105","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1161\/CIRCINTERVENTIONS.111.961912","article-title":"Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry","volume":"4","author":"Bangalore","year":"2011","journal-title":"Circ. Cardiovasc. Interv."},{"issue":"3","key":"10.1016\/j.thromres.2016.04.025_bb0110","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0002-9149(03)00637-4","article-title":"Relation between the degree of procedural anticoagulation and complications after coronary stent implantation","volume":"92","author":"Ashby","year":"2003","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"10.1016\/j.thromres.2016.04.025_bb0115","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/eurheartj\/ehn008","article-title":"Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insight from the STEPLE trial","volume":"29","author":"Montalescot","year":"2008","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.thromres.2016.04.025_bb0120","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0002-9149(03)00117-6","article-title":"Association of an activated clotting time < or =250seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy)","volume":"91","author":"Pinto","year":"2003","journal-title":"Am. J. Cardiol."},{"issue":"5","key":"10.1016\/j.thromres.2016.04.025_bb0125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/MBC.0b013e328304e00d","article-title":"What is the optimal anticoagulation level with argatroban during percutaneous coronary intervention?","volume":"19","author":"Cruz-Gonzalez","year":"2008","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"6","key":"10.1016\/j.thromres.2016.04.025_bb0130","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.amjcard.2004.05.068","article-title":"Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention","volume":"94","author":"Cheneau","year":"2004","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"10.1016\/j.thromres.2016.04.025_bb0135","first-page":"621","article-title":"Heparin and vascular occlusion","volume":"35","author":"Murray","year":"1936","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.thromres.2016.04.025_bb0140","first-page":"407","article-title":"Preliminary report on post-operative treatment with heparin as a preventive of thrombosis","volume":"79","author":"Crafoord","year":"1936","journal-title":"Acta Chir. Scand. Suppl."},{"issue":"5","key":"10.1016\/j.thromres.2016.04.025_bb0145","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1001\/jama.1966.03100180108036","article-title":"Activated coagulation time of whole blood","volume":"196","author":"Hattersley","year":"1966","journal-title":"J. Am. Med. Assoc."},{"issue":"7","key":"10.1016\/j.thromres.2016.04.025_bb0150","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMoa0802944","article-title":"ISAR-REACT 3 Trial Investigators, Bivalirudin versus unfractionated heparin during percutaneous coronary interven- tion","volume":"359","author":"Kastrati","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.thromres.2016.04.025_bb0155","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1001\/jama.1966.03100180108036","article-title":"Activated coagulation time of whole blood","volume":"196","author":"Hattersley","year":"1966","journal-title":"J. Am. Med. Assoc."},{"issue":"16","key":"10.1016\/j.thromres.2016.04.025_bb0160","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jacc.2008.07.026","article-title":"The CIAO (coronary interventions antiplatelet-based only) study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coro- nary intervention","volume":"52","author":"Stabile","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"23","key":"10.1016\/j.thromres.2016.04.025_bb0165","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.thromres.2016.04.025_bb0170","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.thromres.2004.02.012","article-title":"Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration","volume":"113","author":"Casserly","year":"2004","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.thromres.2016.04.025_bb0175","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/0735-1097(94)90636-X","article-title":"Comparison of Hemochron and Hemotech activated coagulation time target values during percutaneous transluminal coronary angioplasty","volume":"23","author":"Avenda\u00f1o","year":"1994","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384816303279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384816303279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T02:36:52Z","timestamp":1567823812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384816303279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":35,"alternative-id":["S0049384816303279"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2016.04.025","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of activated clotting time values for patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2016.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}